University of Groningen Exploring the mechanisms underlying the phenotype of MCAD deficiency with Systems Medicine Martines, Anne-Claire
Hele tekst
(2) Chapter 1 General introduction and outline of the thesis . . .
(3)
(4) General introduction and outline of the thesis. Introduction Ǥ Ǥ Ǥ Ǥ ǡ ȏͳȂͶȐǤǡ ȏͷȂͳ͵ȐǤ Ǥ ȏ͵ǡͳͶȂͳȐǤ. Common acquired metabolic diseases Ǧ ǡ ȏͳͺȐǤ Ǧ Ǥ ǡ ͳͻͷȏͳͻȐǤ ǡ ͳͻΨȋͳʹǤͷΨ͵ͺΨȌȏʹͲȐǡ ǡ ʹȋʹȌǡ ȋ ȌȏͳȂͶȐǤʹǡ ȏʹͳǡʹʹȐǤ ȋ Ȍ ǡ Ǧ ǡ ǡ ǡ ǡ ǡ ǡ ǡ ȏʹͳǡʹ͵ȂʹͷȐǤ ȋ Ȍ ʹͲΨǡ ȏʹȂʹͻȐǤ ȋȌ ȋi.e. Ȍ ȏ͵ͲȂ͵͵ȐǤ Ǧ ǡ ȏ͵ͶȂ͵ȐǤ ȾǦ ǡ ȋȌ Ǥ ǡ ʹ ȋʹȌǤ Ǧ ȏ͵ȐǤ ȾǦ ȏ͵ȐǤ ȏ͵ͺǡ͵ͻȐǤ ǡǦǦ ȏ͵ȐǤ ȏͶͲȐǤ ǡ ǡ ȏͶͲȐǡ ȏͶͲȐǤ ǡ Ǥ Ǥ
(5) ǡ ͳͳ. 1.
(6) Chapter 1 ǡ ȏͳͷǡͶͲǡͶͳȐǤ ǡ ȏͳͷȐǤ ǡ ȋ Ȍǡ ʹǡ ȏͶʹȐǤ
(7) ǡ ǡ ǡ Ϊǡ Ǥǡ
(8) ȋ ȌǤ . Metabolites and common acquired metabolic disease Lipid regulators Ǥ ǡ Ǧ Ǥǡ ǡ ǤͳǣͳǦȏͶ͵ǡͶͶȐǤ Ǥ ȏͶ͵ȂͶȐǤ
(9) Ǧ Ǥ Ǧ Ǧ ȋ ȌǤ de novo Ǥ ǡ Ǧ ǦǦ Ǧ ȋ Ȍǡ ǡ ǡ ǡ ȏͶȐǤ ǡ ǡ Ǧ͵ Ǧ ǡ Ǧ ȏͶͺȂͷͲȐǤ . NAD+ Ϊ ǡ ǡ ǡ ǡ ȏͷͳȂͷ͵ȐǤ
(10) ǡ Ϊǡ ȏͷʹȂͷͶȐǤ
(11) ǡ Ϊ ǤΪ ʹǡΪǦ ͳ ȋ
(12) ͳȌ Ǧ ȾǦ Ǥ
(13) ͳ ǤΪ ǦǦǦ ȏͶʹȐǤΪ
(14) ͳ Ǥ Ϊ ǡ
(15) ͳ Ϊ ǦǦǦ ȏͶʹȐǤΪ Ǧ ǤΪ ǡΪǦ ͵ͺǡ Ǥ ΪǦ Ǥ. ͳʹ.
(16) General introduction and outline of the thesis SIRT1Ϊ Ǧǡ ǡ ȏͶʹȐǤ . Coenzyme A ȏͷͷȂͲȐǤ Ǥ
(17) de novoǡ ǡ ǡ Ǥ
(18) ǡ ȋ ǡ ȋȂ ȌȌǤ
(19) ʹǤ ǡ PANK1 ǡ ǡǦ ȏͷͷȐǤ ob/obʹ ǡ ȋ Ȍǡ ȏͳǡʹȐǤPANK1 ǡ ȾǦ ǡ ǡ Ǥ ǡǡǡ ȏͷͷȐǤ Ǧ ǡ Ǧ ǦǤ ͳǤ
(20) ǡ ǡ ȋ ͷȌǡ Ǥ ǡǤͳ ǡ ȏ͵ȐǤ
(21) ʹǡͳ Ǧ in vitroǡ ȋȌǦ ȋȌȏͶȐǤ . Amino acids ǡ ȏͷȐǤ ǡ Ǥ ǡ Ǧ ȋȌǡǡ Ǥ ȋȌ ǡ ȋ ȌǤ
(22) ǡ Ǧ ȏͶͶǡȐǤ ǡ ȏͶͶȐǤ ʹȏͶͶȐǤ ͳ͵. 1.
(23) Chapter 1. Advances in approaches and methods to study acquired metabolic diseases Bioinformatic approaches Ǧ Ǧ ǡ Ǧ ȋ Ȍǡ ȏȐǤǦ ǡǦ Ǥ ǡǡ Ǥ ȏȐǤ DzǦ dz Ǥ ǡ Ǧ Dz dz Ǧ ǡ Ǧǡ ȋ Ȍ Ȁ ȏͺȐǤ . Experimental models Ǥin vitro Ǥ ǡǡ ʹ ȏͳͶǡͻǡͲȐǤ ǡ ǡ Ǥǡ ǡ Ǥ ǡ ȏͳͶǡͻȐǤ ǡ ȏͳȐǤ ǡin vitro ex vivo ǡ ǡ ȏͻǡʹȐǤ ǡ ǡ Ǧ ǡǦ ȋȌǦ ȏͻǡʹȂȐǤ . Analytical methods and data analysis
(24) ǡ Ǥ DzǦ dz ǡ Ǧ ȏͳͶǡʹͳǡͻǡȂͺͲȐǤ ǡ ȋȌ ǡ Ǧǡ ǡ ȏͷǡǡȂͺ͵ȐǤ ǡ Ǥ ǦǦ ȋ ȌȏͺͶȐǤ ǡ setsǤ ǡ Ǥ ǡ Ǥ . ͳͶ.
(25) General introduction and outline of the thesis ȋȌǡ Ǥ ǡ ǦǦ ȋ
(26) Ȍ Ǧ ǡ ǡ Ǥ ǦǤ Ǧ Ǧǡ Ǧ ȏͺͶȂͺȐǤ ǡ Ǥ . ȏͺͺȐǡ ȏͺͻȐǡ ȏͻͲȐ ȏͻͳȐǡ Ǧ ǡ Dz dz ȏͻʹȐ Dz dzȋ Ȍȏͻ͵ǡͻͶȐ Ǥ Dz dzǦ Ǧ Ǧ ͵ʹǡ εͻͲΨ Ǧ ȏͻʹȐǤ Ǧ Ǥ
(27) ǡ ǡ ǡ ǡ ǡ ǡ Ǥ ȏͻͷȂͳͲͲȐǤ . Systems biology and computational modeling ǡ ǡ ȏͳͲͳȂͳͲͶȐǤ Ǧ ȏͻͷȂͳͲͲǡͳͲͷȂ ͳͳͲȐǤ Ǧ Ǥ Ǧ ǡ Ǧ ǡ ǡǡǡ ȏͳͳͳȐǤ ǡ Ǥ ǤiHepatocytes2322ǡǦ ǡ ȏͻͻȐǤ ʹ ȏͻȐ ȏͳͳʹȐǤ ǡʹͲǡǡ ǡ ǡ ǡǦ Ǧȋ Ȍȏͳͳ͵ȐǤ Ǥ Ǥ ȏͳͳͳǡͳͳͶȐǤ Ǧ ǦǡǦ ȏͳͳͳȐǤ ͳͷ. 1.
(28) Chapter 1 ǡ Ǥ ǡǤ ȋȌ ǡ ǡ Ǥ Ǥ ȏͳͳͷȂͳͳͺȐǤ DzǦdz Ǥ
(29) ǡ Ǥ Ǥ ȏͳͳͻȐǤ ǡ ǡ Ǥ Ǧ ȏͳʹͲȐǤǡ Ǥ
(30) ǡ Ǥ ǡ in silicoǡin vitro or in vivo ȏͳͳͳȐǤ ȏͳʹͳȐǡ ȏͳͲǡͳʹʹȐǡ ǡ ȏͳʹ͵Ȑǡ Ǧ ȾǦ ȏͳʹͶȐǡ ȏͳʹͷȐǡ Ǧ ȏͳͲͺȐǤ ǡ Ǧ Ǥ . Inborn errors of metabolism/Inherited metabolic diseases
(31) ȋ
(32) Ȍ Ǥ
(33) ͳȌ ǡ Ǧ ǡ ʹȌǡ Ǧ Ǧ ǡ͵Ȍ ǡ ȏͳʹȐǤ Ǥ ǡ
(34) ͳȀʹͶͲͲ ʹͲͲ͵ͳȀͳͺͻͶ
(35) ʹͲͳͷȏǡͻǡͳͲǡͳͺǡͳͲʹǡͳʹȐǤ
(36) Ǧ ǦȋȌ ȋȌȏͺȂͳͲǡͳͺǡͳͲʹǡͳʹȐǤ ͳȀͺ͵ͲͲ ʹͲͲʹͲͳͷ ȏͳʹͺȐͳȀͻͲͻ͵
(37) ʹͲͳͷȏȐǤ Ǧ Ǥ
(38) Ǥ ǡ ȏͳͲǡͳͲʹǡͳʹȐǤ ͳ.
(39) General introduction and outline of the thesis. 1. . Common principles underlying IEMs and acquired metabolic diseases
(40) ǡǦ Ǥǡ
(41) ǡǤ ǡ
(42) ǡ ǡ ȏͳͺǡͳͲʹǡͳʹͻȐǤ
(43) ǡ ȋ ȏͳ͵ͲȐȌǡ ǡ ȏͳͺȐǤ
(44) ǡ ǡ ǡ ǡ
(45) ȏͳͺǡͳ͵ͳǡͳ͵ʹȐǤ
(46) Ǥ
(47) ǡ Ǥ ȏͳͺȐǤ
(48) Ǥ Ǥǡ Ǥ Dz ̶ ȋ ̶̶Ȍ Ǥ Ǥ Ǧ ȋȌ ͺǦ ǡȏͳͺǡͳ͵͵ȐǤ ǡ
(49) ȋ Ȍ Ǧ Ǥ ǡ ȋ Ȍ
(50) Ǥ ǡ Ǧ
(51) ȋǦȌǤ
(52) ǡ
(53) Ǥǡ
(54) Ǥ ǡ
(55) Ǥǡ Ǥ
(56) ǡ Ǧ ǡ ǡ Ǧ Ǥ
(57) ʹͲ ȏǡͳͲǡͳͺǡͳ͵ͶȐǤ Ǥ ǡ ǡ ACADM ͳͲΨ ǡ ȏͳ͵ͶȐǤ ACADM ͺǦ ȏͳͺǡͳ͵͵ȐǤ
(58) Ǥ Ϊǡ ǡ Ǥ Ϊ ͳ.
(59) Chapter 1
(60) ȋ
(61) Ȍ ȏͳ͵ͷȂͳ͵ȐǤ
(62) ǡ ǡ ȏͳ͵ͷȂͳͶʹȐǤ
(63) ͵Ǧ Ǧ ǦǦǦ Ǧȋǡ Ȍ ͵Ǧ Ǧ͵Ǧʹȋ ʹȌ ȏͳ͵ͻǡͳͶͲȐǤ ʹ Ǥ
(64) ͵ ȏͳͶͲȐǤǡǡ Ǥ
(65) Ϊ
(66) ȏͳ͵ǡͳͶ͵ǡͳͶͶȐǤ
(67) Ǥǡ
(68)
(69) ǡȋ Ȍ ȋȌȏͷͻǡͲȐǤ . Computational modeling and omics in IEMs ǡ
(70) Ǥ
(71) ǡ ͳǦȏͳͶͷȐǦ ʹΨ͵
(72) ȏͳͶȐǡ ͵ͺ
(73) ȏͻͻȐǤ ʹǤʹǡ ͶΨ Ͷͷ Ǧ
(74) ȏͳͳʹȐǤ
(75) Ǥǡǡ Ǧ Ǧ ȏͳͲͶǡͳͲǡͳͶȐǤ
(76) ǡ Ǥ
(77) Ǧ ȏͳͶͺȐǤ . Mitochondrial fatty-ĂĐŝĚɴ-oxidation (mFAO) and mFAO deficiency Ǧ Ǥ Ǥ Ǧ ǡ Ǧ ȾǦ ȋ Ǧ Ȍ ǦǤ DzȾdz DzȾǦ dz Ƚȋ ȌȾ ȋ Ȍ Ǧ ǡ Ǧ Ǧ Ǥ ǡ Ǥ
(78) ǡ Ǥ Ǥ ȋ ͳȌǤ. ͳͺ.
(79) General introduction and outline of the thesis. 1. Malonyl-CoA. Palmitoyl-CoA. Acyl-carnitine. carnitine. CoASH carnitine. CPT1 CACT. C16. CPT2. C4-C16. Mitochondrion. C4-C16. carnitine. CoASH carnitine. Acyl-carnitine Acyl-CoA. MCKAT C4-C16. Acetyl-CoA CoASH. SCAD. MCAD. LCAD. VLCAD. C4-C6. C4-C12. C8-C16. C12-C16. Enoyl-CoA. Ketoacyl-CoA. MSCHAD C4-C16. NADH + H+ NAD+. H2 O C4-ketoacyl-CoA. CROT C4-C16. Hydroxyacyl-CoA. FAD FADH2. Acetyl-CoA NADH + H+ C4-ketoacyl-CoA NAD+ CoASH. MTP C8-C16. . Figure 1. Schematic representation of the rodent mFAO pathway. ǣ Ǣǣ Ǧ ȋi.e.ǦȀ Ǧ ȌǢ ǣ Ǧ Ǧ ȋi.e. ȌǤ Ǥ. ȋȌ ͳͳͺ Ǥ Ǥ Ǧ ȋ Ȍ ǦȏͳͶͻǡͳͷͲȐǤ Ǧ ǦǤ Ǧ Ǥ Ǧ Ǥ
(80) ȋͳȌǡ Ǧ Ǧ ȋȌǡ
(81)
(82) ȋʹȌǤ ǡ Ǧ Ǧ ǡ Ǧ Ǥ Ǧ Ǧ Ǥ ǡ Ǧ Ǧ ʹǤ Ǧ Ǧ Ǧ Ǥ Ǧ Ǧȋ Ȍ Ǧ ȋ ͳȌǤ
(83) ǡ Ǧ Ǧ ȏͳͷͳȂͳͷ͵ȐǤ Ǥ Ǧ ȏͳͲͺǡͳͷ͵ȐǤ Ǥ ǡ Ǥ Ǥ Ǧ ǣǦǦǡǦǡǦǡǦ Ǧ ǡ ǡ ǡ Ȍ ȋȌ ȋǤǤ ͳǤ͵ǤͻͻǤ͵ ǤǤͳǤ͵ǤͺǤͳȌǤ Ǧ ǡ Ǥ Ǧǡ ȏͺͲȐ ȏͳͷ͵ȐǤ
(84) ǡ Ǧ ͳʹǦͳǡͺǦͳǡͶǦͳʹͶǦ . ͳͻ.
(85) Chapter 1 ǡ ǡ ǡ ǡ Ǧ Ǧͳǡ ͶǦͳ ͶǦ ǡ ǡ Ǥ Ǧ ǡ Ǥ ǡ Ǥ Ǧ Ǧȋ ͳȌǤǦͺ ͵ ȋȌǤ
(86) ǦǦ Ǥ ǡ Ǧ Ǧ ͵ ǣǦ ȋǡǤǤͶǤʹǤͳǤͶǤǤͶǤʹǤͳǤͳͷͲȌǡ Ǧ ȋȀ ǡ ǤǤͳǤͳǤͳǤʹͳͳ ǤǤ ͳǤͳǤͳǤ͵ͷȌ Ǧ ͵ǦǦ Ǧ ȋǡ ǤǤ ʹǤ͵ǤͳǤͳȌȌǡ Ǥ Ǧ Ǥ
(87) Ǧ ǦȀ Ǧ Ǥ Ȁ Ϊ ǡ Ǥ Ȁ Ǧ Ǧ Ϊ Ǥ ȏͳͲͺȐ Ǥ
(88) ȋʹǤͳȉͳͲǦͶȌ Ǥ
(89) ǡ ǡ Ǧ Ǧ ǦǤ ͳͲ͵ȏͳͷ͵ȐǤ Ǧ Ǥ ǡ ǡ Ȁ ǣ ǡ ǦȋǤǤʹǦǦʹǦǦȌʹǦǦ͵Ǧ Ǧǡ ʹǦ Ǧ Ǧ ǦȏͳͷͶȂͳͷȐǤ Ǥ Ǥ ͳǡǡʹǡ ǡǡ ǡǡǡȀ ǡ ȏͳͷ͵ȐǤ ǡ ǡ Ǧ ȋ Ȍ ȏͳͷͺȐǤ
(90) ȏͳͷͺȐǤ ǡ Ȁ ȋ Ͷ Ȍ ȏͳͷͻȐǤ
(91) ǡ Ǧ Ǧǡ Ǧ Ǧ Ǧ Ǧ ȏͳͲȐǤ ǡ Ȁ ȋ
(92) ȌǡȀ ʹȋ
(93) Ȍ ǦǦ ȏͳͳȂͳ͵ȐǤ ǡ Ǧ ͶǦ Ǧ Ǥ ǡ Ǧ ǡ ǦǤ ʹͲ.
(94) General introduction and outline of the thesis. 1. . mFAO deficiency ȏͳͷ͵ǡͳͶȐǤ
(95) ǡ Ǧ ǡ Ǧ Ǧ Ǥ ǡ ǡ ǯ ǡ ȏͳͲͻǡͳͷ͵Ȑǡ Ǥ ǡ ǡ EǦ Ǥǡ ǡ EǦǤ Ǧ ȋȌ ǡ ǡȏͳͷ͵Ȑ ȏͳͷ͵ȐǤ ǡ ȏͳͷ͵ǡͳͷȐǤ ǡ ǡ ǡ Ǥ Ǥ ȏͳͷ͵ǡͳͷǡͳȐǤ ǡ
(96) ǡ Ǧ ǡ ȏͳ͵Ͷǡͳͷ͵ǡͳͷǡͳȂͳͳȐǤ . Medium-chain acyl-CoA dehydrogenase (MCAD) deficiency ȋ
(97) ʹͲͳͶͷͲȌ ǡ ͳ ͲͲ ȏͳͳǡͳ͵ͲȐǤ
(98) Ǥ ǡ Ǥ Ǥ
(99) ǦǦ Ǥͻͺͷε ACADM ǡ ǡ Ψ ȏͳ͵ͶȐǤ ͵ͲͶȋǤ͵ͲͶȌǤ ǡ ȏͳʹȂͳͷȐǤǦ ȋ Ȍ ȏͳͷ͵ǡͳͶȐǤ ǡ ǡ ǡ ǡ ǡ ǡ ǡ ȏͳ͵Ͳǡͳ͵ͳǡͳͷȐǤ ǡ ǡ Ǧ Ǧ Ǧ ǦͳͲ ͺ ͳͲ ȏͳͷǡͳͲǡͳȂͳͺ͵ȐǤ ͳͲΨ ȏͳ͵ͶȐǤ ǡ Ǥ. ʹͳ.
GERELATEERDE DOCUMENTEN
ͲǤͲͲ ͲǤͲͲ ͲǤͲͲ ͲǤͲͲ ͲǤͲͳ ʹǤͳ ͲǤͷ ͳǤ͵ͳ ͲǤͲ ͲǤͲͳ ͲǤͲͲ ͲǤͲͳ ͲǤͲʹ ͲǤͲͳ ͲǤͲʹ ͲǤͲͳ ͲǤͲͳ ͲǤͲͳ ͲǤͲ͵ ͲǤͲͶ ͲǤͲͶ ͲǤͲ ͲǤͲͳ ͲǤͲͷ ͲǤͲʹ ͲǤͲͳ ͲǤͲͳ ͲǤͲͲ ͲǤͲͲ ͲǤͲͲ ͲǤͲͲ ͲǤͲͲ ͲǤͲͲ ͲǤͲͲ
Flux control coefficients of model with ACS knockdown to 1% of its reference value JNAD production JCPT1C16 [CoASH]MAT [palmitoyl-CoA]CYT ʹͷɊ ͳͲͲɊ ʹͷɊ ͳͲͲɊ ʹͷɊ ͳͲͲɊ
of Pediatrics, Center of Liver, Digestive and Metabolic Diseases, University of Groningen, Groningen, University Medical Center Groningen, Groningen, The Netherlands, 2 Department
Computational rat dynamic model of isolated mFAO with C16-specific CPT1 solid lines, with C16-C4 sensitive CPT1 dashed lines and with C16-C4 sensitive CPT1 at twice larger Vmax
Copyright Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the authors and/or
JCPT1C16 [CoASH]MAT JNAD production [palmitoyl-CoA]CYT ʹͷɊ ͳͲͲɊ ʹͷɊ ͳͲͲɊ ʹͷɊ ͳͲͲɊ Vcpt1 0.59 0.00 0.61 0.06 -0.24 -1.11 Vfcact ͲǤͲͳ ͲǤͲͲ ͲǤͲͳ ͲǤͲͲ ͲǤͲͲ ͲǤͲͲ
Exploring the mechanisms underlying the phenotype of MCAD deficiency with Systems Medicine: from computational model to mice to man..
Aims: To review the literature about the dosing regimen, duration, effects, and side effects of oral, intravenous, intranasal, and subcutaneous routes of administration of